Efficient Induction of Apoptosis by Wee1 Kinase Inhibition in Hepatocellular Carcinoma Cells

Tomomi Kogiso¹,², Hikaru Nagahara², Etsuko Hashimoto¹, Shunichi Ariizumi³, Masakazu Yamamoto³, Keiko Shiratori¹

¹ Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan, ² Aoyama hospital, Tokyo Women's Medical University, Tokyo, Japan, ³ Institute of Gastroenterology, Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan

Abstract

Transforming growth factor-β1 (TGF-β1) potently inhibits human hepatocellular carcinoma (HCC) cell growth. Here we demonstrated that TGF-β1-induced apoptosis is mediated by decreased phosphorylation of cdc2 at Tyr15 accompanied by down-regulation of Wee1 kinase expression. As expected from these results, a Wee1 kinase inhibitor efficiently induced apoptosis in HCC cells in the absence of TGF-β1 treatment. In surgically resected samples, Wee1 kinase was expressed in moderately to poorly differentiated HCC, whereas no Wee1 kinase expression was observed in non-cancerous tissue, including cirrhotic tissue. Our results suggest that Wee1 kinase inhibitors may be a practical novel therapeutic option against advanced HCC.

Citation: Kogiso T, Nagahara H, Hashimoto E, Ariizumi S, Yamamoto M, et al. (2014) Efficient Induction of Apoptosis by Wee1 Kinase Inhibition in Hepatocellular Carcinoma Cells. PLoS ONE 9(6): e100495. doi:10.1371/journal.pone.0100495

Introduction

Human hepatocellular carcinoma (HCC) is a widespread disease brought about by long-term liver inflammation [1,2]. Although surgical and percutaneous radiofrequency ablation improve patient survival, new therapeutic options are needed to achieve effective treatment of advanced HCC [3–6]. Apoptotic induction by chemotherapy and low molecular weight material delivery are both promising options [6,7].

Previous studies showed that transforming growth factor-β1 (TGF-β1) stimulates cell proliferation in non-epithelial cells, such as fibroblasts and stellate cells, whereas it suppresses cell growth in both rodent and human HCC cells by inducing apoptosis or cell cycle arrest [8,9]. However, the main molecules involved in TGF-β1-induced apoptosis in HCC cells are largely unknown.

In this study, we evaluated human HCC cell lines to elucidate TGF-β1-induced apoptotic mechanisms. Our results demonstrated that we efficiently induced apoptosis in HCC cell lines using a Wee1 kinase inhibitor. These results may lead to development of novel therapeutic options against human HCC.

Materials and Methods

Cell culture

The human hepatocellular carcinoma cell line, HuH7, was purchased from the Riken Cell Bank (Wako, Saitama, Japan). The cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 5% heat-inactivated fetal calf serum (FCS). TGF-β1-induced apoptosis-resistant HuH7 cells (HuH7R) were established from the HuH7 line by maintaining the cells with low-dose TGF-β1 (0.2 μg/mL; R&D Systems, Minneapolis, MN, USA) for 1-2 months. TGF-β1-induced apoptotic resistance was confirmed by flow cytometry following TGF-β1 treatment.

Flow cytometric analyses

Cells were trypsinized, harvested, and fixed with 70% ethanol at −20°C for 1 h. After washing with phosphate buffered saline (PBS), the cells were stained with propidium iodide (PI), and the cell cycle was analyzed using a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).

Cell treatment

For TGF-β1 treatment, cells were incubated in medium containing 0.1% FCS and 2 μg/mL TGF-β1. To counteract TGF-β1-mediated apoptosis, 20 μM roscovitine (Calbiochem, Nottingham, UK) was added to the medium 1 h prior to TGF-β1.

PD166285, a Wee1 kinase inhibitor, was provided by Pfizer (Ann Arbor, MI, USA) and used at a concentration of 200 nM. Roscovitine (20 μM) was also added 1 h prior to PD166285 administration to inhibit cdc2 activity resulting from the inhibition of PD166285-mediated apoptosis.

Immunoprecipitation and immunoblotting

Cells were lysed using 0.4 mL E1A lysis buffer [ELB: 50 mM HEPES (pH 7.2) 250 mM NaCl, 2 mM EDTA, 0.1% Nonidet P-40, 1 mM DTT, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 50 μg/mL phenylmethylsulfonyl fluoride, 0.5 mM Na3PO4, 0.1 mM
NaVO₄, and 5.0 mM NaF (all reagents were purchased from Sigma-Aldrich, St Louis, MO, USA). The lysed cell solution was centrifuged, protein G or cdc2 antibodies were added to the supernatant, and the mixture was incubated at 4°C overnight. Immunoblots were prepared as described previously [10] and probed with anti-Wee1, anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or anti-cdc2-phospho-Tyr15 (Cell Signaling Technology, Danvers, MA, USA).

Kinase assay
TGF-β1-treated or untreated whole cell extracts were incubated with an anti-cdc2 antibody overnight at 4°C. The precipitates were washed and incubated with α-³²P-ATP for 20 min at 30°C in a kinase solution [10] containing histone H1 (Sigma-Aldrich), as a substrate of cdc2, and then subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The incorporation rate of ³²P into histone H1 was measured using a PhosphoImager (BioRad Laboratories Hercules, CA, USA).

Transfection of short interfering RNA (siRNA)
siRNAs against Wee1 kinase were synthesized and cloned into a piGENEPURhU6 vector (Toyobo, Tokyo, Japan) and named psiWee1. psiWee1 was transfected into HuH7 cells using OptiFect Reagent (Invitrogen, Carlsbad, CA, USA). The target sequences against Wee1 kinase were GGCAGAAGATGATCATATG (18-2) and GGCAGAAGCTGATCTTCTC (18-3).

Immunohistostaining
HCC tissue samples (n = 26) were obtained by surgical resection and authorized for immunohistochemical analysis after receiving written informed consent from each patient. This study was approved by the ethics committee of Tokyo Women’s Medical University Hospital (Tokyo, Japan). The tissue sections were placed into 10 mM EDTA (pH 9.0), heated at 90–95°C for 40 minutes, and then incubated with normal rabbit serum and reacted with an anti-Wee1 antibody (1:200; Santa Cruz Biotechnology). We used DAKO Envision + System (DAKO, Glostrup, Denmark) horseradish peroxidase (HRP) as a secondary antibody.
according to the manufacturer’s instructions and detected signals using 3,3′diaminobenzidine (DAB) as a substrate.

Statistical analyses

Significant differences between groups were determined using a Student’s t-test or a chi-square test. P < 0.05 was considered to be statistically significant.

Results

TGF-β1 induces apoptosis in HCC cells by cdc2 activation

TGF-β1 administration resulted in an increased proportion of the HuH7 cell population in the sub-G1 (demonstrative of apoptosis) and G1 phases (demonstrative of cell cycle arrest) (Figure 1A). FACS analyses revealed that the sub-G1 phase cell population increased from approximately 0.7% to 7.7%, and HuH7 cells in the G1 phase increased from approximately 69% to 87% after 48 h of TGF-β1 treatment (Figure 1A and B). Consistent with previous reports [11], cdc2 was activated after TGF-β1 treatment in HuH7 cells (Figure 1B). We then examined whether cdc2 activation was necessary for the induction of apoptosis. We established an apoptosis-resistant HuH7 clone (HuH7R) that we isolated after long-term culture under low TGF-β1 concentration conditions. In these HuH7R cells, cdc2 was not activated, even after TGF-β1 treatment (Figure 1B). To further validate the role of cdc2 activation in the induction of apoptosis after TGF-β1 stimulation, we pre-treated HuH7 cells with roscovitine, a chemical inhibitor of cdc2. Roscovitine pretreatment markedly decreased the sub-G1 cell population and the cdc2 activity even after TGF-β1 treatment (Figure 1B). These results suggest that cdc2 activation is important for TGF-β1-induced apoptosis.

Cdc2 activity is regulated by its phosphorylation at Tyr15 [12–16]; thus, we examined Wee1 kinase expression and cdc2 Tyr15 phosphorylation after TGF-β1 treatment. As predicted, Wee1 kinase expression was down-regulated, and cdc2 Tyr15 was dephosphorylated in TGF-β1-treated cells (Figure 1C). Apoptosis-resistant HuH7R cells also preserved Wee1 kinase expression and Tyr15 phosphorylation of cdc2 even after TGF-β1 stimulation (Figure 1C). In a time course experiment, down-regulation of Wee1 expression and Tyr15 dephosphorylation of cdc2 commenced approximately 24 h after TGF-β1 treatment and was consistent with the initiation of apoptosis (Figure 1D).

Targeting Wee1 kinase induces apoptosis in HCC cells

Given the above findings, we tested whether apoptosis could be induced in HCC cells by inhibiting Wee1 kinase using a specific Wee1 kinase inhibitor, PD166285 [17,18], or siRNA against Wee1 kinase in the absence of TGF-β1 stimulation. Treatment with PD166285 alone increased the sub-G1 population of HuH7 cells in a concentration-dependent manner (Figure 2A and B).
Wee1 kinase is expressed in moderately to poorly differentiated HCC. A-C, Wee1 kinase was stained with anti-Wee1 antibodies in surgically resected HCC samples (\( \checkmark \) HCC lesion). Anti-Wee1 antibody staining revealed mostly nuclear localization in Wee1 kinase-positive cells. The magnification is 40 x (A), 100 x (B), or 200 x (C). Scale bars = 200 \( \mu\)m. D, Wee1 kinase is expressed in moderately to poorly differentiated HCC. A chi-square test revealed significant differences (p = 0.0026). (NC, Non-cancerous lesion, Mod., Moderately).

Next we investigated the effect of roscovitine treatment on PD166285-mediated apoptosis, since roscovitine can inhibit TGF-\( \beta \)-mediated apoptosis (Figure 1B). As expected, roscovitine exclusively inhibited apoptosis mediated by the Wee1 kinase inhibitor (Figure 2A), suggesting that this apoptotic pathway is mediated by an active form of cdc2. Although these are possible molecular mechanisms for the induction of apoptosis by the Wee1 kinase inhibitor, we do not fully exclude other possibilities.

We subsequently used two different siRNAs (18-2 and 18-3) targeting separate sites of Wee1 kinase mRNA to inhibit Wee1 kinase expression. HuH7 cells were transfected with these Wee1 siRNAs, and the resulting cell number and sub-G1 population of the transfectants were analyzed (Figure 2C and D). Both siRNAs induced apoptosis efficiently, compared with vector alone (Figure 2C), in a concentration-dependent manner (Figure 2D).

Wee1 kinase is expressed in moderately to poorly differentiated HCC but not in non-cancerous lesions

To determine the expression of Wee1 kinase in human HCC, we obtained tissue samples from surgically resected HCC and performed immunohistochemistry. Wee1 kinase immunohistochemistry revealed positive nuclear staining in cells located at the margins of HCC and non-cancerous lesions (Figure 3A–C). Wee1 kinase expression was detected in 7/17 (41.2%) moderately differentiated HCC tissues and 1/5 (20%) poorly differentiated HCC tissues, while there were no apparent positive cells in four well-differentiated HCC tissues and the corresponding 26 non-cancerous lesions (Figure 3D, p = 0.0026).

Discussion

TGF-\( \beta \) potently inhibits HCC cell growth by inducing cell cycle arrest and/or apoptosis [19–22]. Here we showed that the induction of apoptosis by TGF-\( \beta \)-1 in HCC cells is mediated by de-phosphorylation of cdc2 Tyr15 (\( \checkmark \), the active form of cdc2). This cdc2 activation was induced by Wee1 kinase down-regulation. In addition, we induced apoptosis in HCC cells by inhibiting Wee1 kinase using a specific inhibitor or siRNA.

Previous studies have identified several molecules that may play key roles in the induction or inhibition of apoptosis by TGF-\( \beta \)-1 [23,24]. We determined here that cdc2 activation due to decreased Tyr15 phosphorylation may be crucial for TGF-\( \beta \)-1-induced apoptosis in HCC cells. We observed decreased Wee1 kinase expression after TGF-\( \beta \)-1 treatment, and cdc2 phosphorylation is regulated by Wee1 kinase. Therefore, it is possible that TGF-\( \beta \)-1-mediated apoptosis was induced by a Wee1/cdc2 axis. However, the molecular mechanisms underlying the TGF-\( \beta \)-1-mediated down-regulation of Wee1 kinase are unclear.

In surgically resected samples, Wee1 kinase was over-expressed in HCC, particularly in moderately to poorly differentiated or advanced HCC. Wee1 kinase is a negative regulator of cdc2; thus, questions remain regarding the role of increased Wee1 kinase in HCC.

Based on our results, we focused on Wee1 kinase as a possible therapeutic target. As expected, a kinase inhibitor and siRNAs against Wee1 kinase efficiently induced apoptosis in HCC cells in the absence of TGF-\( \beta \)-1. Because TGF-\( \beta \)-1 is a multifunctional cytokine, it may not be a practical therapeutic option.

Overexpression of Wee1 kinase has been reported in other tumor types, including brain tumors and leukemia, and the usefulness of Wee1 kinase inhibitor has been demonstrated [25,26]. In brain tumors, the expression of Wee1 kinase was upregulated only in tumor cells, not in normal cerebellum, and the upregulated kinase had an important role in cancer cell survival [25]. Wee1 kinase negatively regulates G2/M phase by inhibiting the initiation of mitosis after DNA damage is repaired [27–29]. Thus, it is thought that Wee1 kinase abrogates premature mitotic entry and subsequent cell death [28,29]. Therefore, the inhibition of Wee1 kinase may be a promising new therapeutic strategy in Wee1 kinase-overexpressing carcinomas [25].

Wee1 kinase was expressed focally in the carcinoma tissues. Thus, for clinical applications, there would be some limitations on effectiveness. However, a Phase II trial using a Wee1 kinase inhibitor for the treatment of advanced solid cancers is currently underway [29,30]; thus, the use of this type of inhibitor may be a realistic therapeutic option against advanced HCC.

Acknowledgments

We thank Dr. M. Kobayashi for the useful advice regarding immunostaining and R. Furukawa for assistance with the experiments.

Author Contributions

Conceived and designed the experiments: TK HN EH KS. Performed the experiments: TK HN. Analyzed the data: TK HN. Contributed reagents/materials/analysis tools: TK HN SA MY. Contributed to the writing of the manuscript: TK HN.
References

1. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22: 5093–5107.
2. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461–466.
3. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429–442.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 78–89.
5. Bruix J, Sherman M, Practice Guidelines Committee AeAftSoLD (2005) Management of hepatocellular carcinoma. Hepatology 42: 1280–1286.
6. Gauthier A, Ho M (2012) Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res.
7. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAS/RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11831–11838.
8. Massagat J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and inheritable disorders. Cell 103: 295–309.
9. Massagat J (2001) G1 cell-cycle control and cancer. Nature 432: 298–306.
10. Nagahara H, Ezhevsky SA, Vocero-Akbani AM, Kaldis P, Solomon MJ, et al. (1999) Transforming growth factor beta targeted inactivation of cyclin- dependent kinase 2 (CdK2) complexes by inhibition of CdK2 activating kinase activity. Proc Natl Acad Sci U S A 96: 14961–14966.
11. Choi KS, Eom YW, Kang Y, Ha MJ, Rhee H, et al. (1999) Cdc2 and Cdk2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of Thr161 as an essential in vivo phosphorylation site. New Biol 4: 51–58.
12. Krek W, Eom YW, Kang Y, Ha MJ, Rhee H, et al. (1999) Cdc2 and Cdk2 kinase activation in vertebrates. EMBO J 10: 3321–3329.
13. Krek W, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390.
14. Gauthier A, Ho M (2012) Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res.
15. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAS/RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11831–11838.
16. Solomon MJ, Lee T, Kirschner MW (1992) Role of phosphorylation in p34cdc2 activation: identification of an activating kinase. Mol Biol Cell 3: 13–27.
17. Wang Y, Li J, Brooker RN, Krakker A, Lawrence T, et al. (2001) Radiosensitization of p53 mutant cells by PD0166283, a novel G2 checkpoint abrogator. Cancer Res 61: 8211–8217.
18. Li J, Wang Y, Sun Y, Lawrence TS (2002) Wild-type TP53 inhibits G2-phase checkpoint abrogation and radiosensitization induced by PD0166283, a WEE1 kinase inhibitor. Radiat Res 157: 322–330.
19. Ng, CW, Chen CH, Chen CC, Chen JY, Yu YH, et al. (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 4: 51–58.
20. Claussen GF, Hanna SR (2000) A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci U S A 97: 9498–9503.
21. Perlman R, Schiarmann WP, Brooks MW, Lodish HF, Weinberg RA (2001) TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 3: 708–714.
22. Yilmaz M, Maass D, Tiwari N, Waldmeier L, Schmidt P, et al. (2011) Transcription factor IKKepsilon protects from TGFbeta-induced cell-cycle arrest and apoptosis. EMBO J 30: 4489–4499.
23. O’Connor DS, Wall NR, Porter AC, Aliieri DC (2002) A p34cdc2 survival checkpoint in cancer. Cancer Cell 2: 43–54.
24. Chang CC, Heller JD, Kuo J, Huang RC (2004) Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdk2 and survivin expression. Proc Natl Acad Sci U S A 101: 13239–13244.
25. Harris PS, Venkataraman S, Almova I, Birks DK, Balakrishnan I, et al. (2014) Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer 13: 72.
26. Porter CC, Kim J, Fosmite S, Gearhart CM, van Lenden A, et al. (2012) Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26: 1266–76.
27. Janssen A, Medema RH (2011) Mitosis as an anti-cancer target. Oncogene 30: 2799–809.
28. Russell P, Nurse P (1987) Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 49: 559–67.
29. De Witt Hamer PC, Mir SE, Nooke D, Van Noorden CJ, Wurdinger T (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 17: 4200–4207.
30. Leijen S, Reijnen JH, Schellens JH (2010) Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 5: 87–191.